Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429427 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL19258528 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL13456716 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL5995916 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL29381813 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL23547977 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL859095 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL13429418 | 1.00 | ADORA3 (0.59) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL22112122 | 0.89 | PI4K2A (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL14946285 | 0.89 | PI4K2A (0.53) | ADORA3ADORA2API4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495241-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | ADORA3 715/4885ADORA2A 696/4885PI4KA 3880/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA3 3807/4885ADORA2A 3422/4885PI4KA 3957/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | ADORA3 335/4885ADORA2A 393/4885PI4KA 618/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | ADORA3 1914/4885ADORA2A 3057/4885PI4KA 2231/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | ADORA3 164/4885ADORA2A 224/4885PI4KA 2324/4885 |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | ADORA3 219/4885ADORA2A 122/4885PI4KA 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.